《上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

[1]周小燕,徐望明,董兰,等.阿托西班与利托君治疗早产临床疗效的系统评价[J/CD].中华妇幼临床医学杂志(电子版),2014,(02):170-176.

Zhou Xiaoyan, Xu Wangming, Dong Lan, et al. Atosiban Versus Ritodrine in the Treatment of Preterm Labour: A Systematic Review [J/CD]. Chinese Journal of Obstetrics & Gynecology and Pediatrics (Electronic Edition), 2014, (02):170-176.

点击复制

阿托西班与利托君治疗早产临床疗效的系统评价(PDF

《中华妇幼临床医学杂志(电子版)》[ISSN:1673-5250/CN:11-9273/R] 卷: 期数: 2014年02期 页码: 170-176 栏目: 论著 出版日期: 2014-04-30

Title: Atosiban Versus Ritodrine in the Treatment of Preterm Labour: A

Systematic Review

作者: 周小燕;徐望明;董兰;王慧明;罗增丽;解美婷

430060, 武汉大学人民医院生殖中心

Author(s): Zhou Xiaoyan; Xu Wangming; Dong Lan; Wang Huiming; Luo Zengli; Xie

Meiting.

Reproduction Center, Renmin Hospital of Wuhan University, Wuhan 430060,

Hubei Province, China.

关键词: 评价研究; 早产; 阿托西班; 利托君; 系统评价

Keywords: Evaluation studies; Premature birth; Atosiban; Ritodrine; Systematic review

分类号: -

DOI: -

文献标识码: -

Abstract:

摘要: 目的 探讨阿托西班 (atosiban)与利托君(ritodrine)治疗早产的临床疗效及安全性。

方法 根 据系统评价原则,计算机全面检索相关文数据库,收集国内外有关阿托西班和利托君治疗早产的随机对照试验(RCT),对符合本研究纳入标准的临床研究采用 RevMan 5.1软件进行 Meta 分析。 结果 通 过文献检索,共计4篇RCT文献符合本研究纳入标准,共计纳入420例患者。①3篇英文文献的方法学质量高,研究对象一致,均为早产患者,进行 Meta 分析的结果显示,阿托西班组与利托君组在治早产的有效率、延长分娩时间、增加新生儿出生体质量、降低新生儿窒息率及围生儿死亡率等方面较,差异无统计学意义(P>0.05);但孕妇心动过速发生率与因母体不良反应中断治疗率,阿托西班组较托君组显著降低,且差异均有统计学意义[RR=0.02,95% CI (0.01~0.08),P<0.01; RR=0.03,95 CI (0.01~0.15),

P <0.01]。②1篇中文文献的方法学质量较差,且研究对象为先兆早产患者,独立进行描述性分析结果显示,阿托西班与利托君治疗先兆早产在显效时间、延长妊娠时间、保胎成功率、足月分娩率、增加新生儿出生体质量与降低不良反应发生率方面比较,差异均无统计学意义(P >0.05)。结论阿托西班治疗早产的临床疗效与利托君相当,国内外研究中比较二者不良反应发生率的结果有所不同,尚不能断定阿托西班治疗早产的安全性明显优于利托君。尚需更多国内外高质量、大样本的RCT结合成本 效益

分析,以更全面、客观、正确地评价阿托西班在治疗早产中的确切临床价值。

Objective To explore the clinical efficacy and safety between atosiban and

ritodrine in treatment of preterm labour. Methods The relevant data base were

导航/NAVIGATE
本期目录/Table of Contents
下一篇/Next Article
上一篇/Previous Article
上一篇/Previous Article

工具/TOOLS
引用本文的文章/References
下载 PDF/Download PDF(1861KB)
立即打印本文/Print Now
推荐给朋友/Recommend

统计/STATISTICS
摘要浏览/Viewed
全文下载/Downloads

4
评论/Comments

RSS XML

searched according to the principles of systematic review to collect all the randomized controlled trials(RCT) involving treatment of preterm labour using atosiban and ritodrine. According to treatment strategies, the subjects were divided into atosiban group and ritodrine group. Meta analysis of including studies was performed by Rev Man 5.1 software. Results A total of 4 pieces RCT were included with 420 subjects. ①Three of them were English literature, RCT with high quality included patients of preterm labour. The Meta analysis showed there were no statistic differences in tocolytic efficacy, gestational age at delivery, birth weight of neonatal, rates of neonatal asphyxia or perinatal death between two groups ($\,$ P $\,$ >0.05) . The incidence of maternal tachycardia and early drug termination due to adverse events in atosiban group were substantially lower than those in ritodrine group [RR =0.02, 95% CI (0.01 0.08), P <0.01. R =0.03,95% CI (0.01 0.15). P <0.017, respectively. <a>One Chinese study withrelatively lower quality included patients of threatened preterm labour. A descriptive analysis conducted independently showed that there were no significant differences between two groups in time to effect, prolonged pregnancy duration, tocolysis rate, full term delivery rate, birth weight or adverse events rate(P >0.05). Conclusions Atosiban treatment of preterm labour was better than that of ritodrine. There had difference between domestic and abroad studies in term of incidence of adverse events. It is quite necessary to perform more high quality and large scale RCT in combination with cost effectiveness evaluation to assess the exact clinic value of atosiban in treatment of preterm labour more reliably.

参考文献/REFERENCES

-

备注/Memo: 收稿日期: 2013 11 20修回日期: 2013 12 30

更新日期/Last Update: 2014-04-30